文献速递甲状腺疾病

伴高级别特征的甲状腺乳头状癌与低分化甲状腺癌的临床病理、分子特征及预后比较

Papillary Thyroid Carcinoma with High-Grade Features Versus Poorly Differentiated Thyroid Carcinoma: An Analysis of Clinicopathologic and Molecular Features and Outcome.
PubMed 文献 · Thyroid · 2021-01-19

本研究比较了15例伴高级别特征的甲状腺乳头状癌(PTC HGF)与47例低分化甲状腺癌(PDTC)的临床病理、分子特征及预后。PTC HGF组pT4病变率(53% vs. 13%,p=0.0027)和淋巴结转移率(73% vs. 38%,p=0.049)更高,疾病特异性生存更差(p<0.001),且BRAFV600E突变率(42% vs. 3%,p=0.003)和1q相对增益率(67% vs. 15%,p=0.002)更高。结果表明PTC HGF侵袭性更强,应被视为独立于PDTC的亚组。

要点

  • PTC HGF定义:保留PTC核特征,核分裂≥5/10 HPF和/或肿瘤坏死。
  • PTC HGF较PDTC pT4病变和淋巴结转移率更高,生存更差。
  • PTC HGF分子特征与PDTC不同,BRAFV600E突变和1q增益更常见。

核心结论

  • 伴高级别特征的甲状腺乳头状癌(PTC HGF)侵袭性行为强于低分化甲状腺癌(PDTC),应被识别为独立实体。

研究设计与样本

  • 回顾性比较研究,纳入连续符合PTC HGF标准的肿瘤15例和符合WHO标准诊断的PDTC 47例。
  • 比较两组临床病理特征、随访数据及靶向二代测序结果。

主要发现

  • PTC HGF组pT4病变率为53%,PDTC组为13%(p=0.0027)。
  • PTC HGF组淋巴结转移率为73%,PDTC组为38%(p=0.049)。
  • Kaplan-Meier估计显示PTC HGF组疾病特异性生存差于PDTC组(p<0.001)。
  • 在广泛侵袭性PDTC亚组分析中,PTC HGF组疾病特异性生存仍更差(p=0.040)。
  • PTC HGF组BRAFV600E突变率为42%,PDTC组为3%(p=0.003);1q相对增益率为67% vs. 15%(p=0.002);基因融合有更多趋势(25% vs. 3%,p=0.052)。

关键数值与推荐

  • PTC HGF定义为保留PTC核特征且核分裂数≥5/10个连续高倍视野和/或肿瘤坏死。
  • PDTC定义依据世界卫生组织(WHO)标准。

临床怎么用

  • 病理诊断中应识别PTC HGF,因其侵袭性行为强于PDTC,需更密切随访。
  • PTC HGF与PDTC分子特征不同,支持将PTC HGF作为独立分组进行管理。

局限性

  • 样本量较小(PTC HGF 15例,PDTC 47例),结论需更大样本验证。
  • 回顾性设计可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Similar to poorly differentiated thyroid carcinoma (PDTC), papillary thyroid carcinoma with high-grade features (PTC HGF) demonstrates increased mitotic activity and/or necrosis; however, PTC HGF is excluded from the World Health Organization (WHO) definition of PDTC based on maintained nuclear features of PTC. Methods: Consecutive tumors that met criteria for PTC HGF, defined as tumors with maintained nuclear features of PTC and mitoses numbering 5 or more per 10 contiguous high-power fields and/or tumor necrosis, and PDTC (defined as per the WHO criteria) were identified. Clinicopathologic characteristics, follow-up data, and targeted next-generation sequencing results were compared between groups. Results: There were 15 PTC HGF and 47 PDTC. PTC HGF was associated with a higher rate of pT4 disease (53% vs. 13%, p = 0.0027) and lymph node metastases (73% vs. 38%, p = 0.049). The disease-specific survival was worse for patients with PTC HGF compared with those with PDTC using Kaplan-Meier estimation (p < 0.001) and was worse in subgroup analysis evaluating patients with widely invasive PDTC (i.e., those with a similar rate of pT4 disease) and PTC HGF (p = 0.040). PTC HGF had a higher BRAFV600E mutation rate (42% vs. 3%; p = 0.003), a trend toward more gene fusions (25% vs. 3%; p = 0.052), and a higher rate of relative gain of 1q (67% vs. 15%; p = 0.002) than PDTC. Conclusions: Our results demonstrate that PTC HGF are important to recognize based on their aggressive behavior. The molecular differences between PTC HGF and PDTC suggest that PTC HGF should be considered a distinct group from PDTC.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Wong KS, Dong F, Telatar M, et al. Papillary Thyroid Carcinoma with High-Grade Features Versus Poorly Differentiated Thyroid Carcinoma: An Analysis of Clinicopathologic and Molecular Features and Outcome. Thyroid. 2021. PMID: 33143568. doi:10.1089/thy.2020.0668

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。